Side-by-side research comparison of Liraglutide and Semaglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 377 Liraglutide studies and 662 Semaglutide studies.
| Liraglutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 377 | 662 |
| Highest evidence tier | rct | — |
| Evidence tier mix | rct · 8 cohort · 2 review · 2 in vitro · 2 preclinical animal · 1 | n/a |
| Studies with explicit sample size | 5 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Liraglutide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 9 Liraglutide batches across 4 manufacturers, 99.58% avg purity.
We tested 2418 Semaglutide batches across 608 manufacturers, 99.66% avg purity.
We hold deeper lab coverage on Semaglutide (2418 batches tested). Semaglutide edges ahead on average measured purity (99.58% vs 99.66%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Liraglutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.